Anas Younes

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. pmc Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma
    Anas Younes
    The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Clin Oncol 30:2183-9. 2012
  2. doi request reprint From drug discovery to biomarker-driven clinical trials in lymphoma
    Anas Younes
    Department of Lymphoma Myeloma, MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Nat Rev Clin Oncol 9:643-53. 2012
  3. doi request reprint Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial
    Anas Younes
    Department of Lymphoma and Myeloma, The University of Texas, M D Anderson Cancer Center, Houston, TX 77030, USA
    Lancet Oncol 12:1222-8. 2011
  4. doi request reprint Phase I study of a novel oral Janus kinase 2 inhibitor, SB1518, in patients with relapsed lymphoma: evidence of clinical and biologic activity in multiple lymphoma subtypes
    Anas Younes
    Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 30:4161-7. 2012
  5. doi request reprint Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/refractory B-cell lymphoma
    Anas Younes
    Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 30:2776-82. 2012
  6. doi request reprint Panobinostat in patients with relapsed/refractory Hodgkin's lymphoma after autologous stem-cell transplantation: results of a phase II study
    Anas Younes
    MD Anderson Cancer Center, 1515 Holcombe Blvd, Unite 429, Houston, TX 77030, USA
    J Clin Oncol 30:2197-203. 2012
  7. pmc Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma
    Anas Younes
    Departments of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Blood 119:4123-8. 2012
  8. pmc Histone deacetylase inhibitors in Hodgkin lymphoma
    Daniela Buglio
    Department of Lymphoma Myeloma, 1515 Holcombe Boulevard, Box 429, Houston, TX 77030, USA
    Invest New Drugs 28:S21-7. 2010
  9. doi request reprint CD30-targeted antibody therapy
    Anas Younes
    Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Curr Opin Oncol 23:587-93. 2011
  10. ncbi request reprint Initial trials of anti-CD80 monoclonal antibody (Galiximab) therapy for patients with relapsed or refractory follicular lymphoma
    Anas Younes
    M D Anderson Cancer Center, University of Texas, Houston, TX 77030 4009, USA
    Clin Lymphoma 3:257-9. 2003

Research Grants

  1. Clinical Activity of 17-AAG in Lymphoma
    Anas Younes; Fiscal Year: 2007

Collaborators

Detail Information

Publications117 found, 100 shown here

  1. pmc Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma
    Anas Younes
    The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Clin Oncol 30:2183-9. 2012
    ..In phase I studies, brentuximab vedotin demonstrated significant activity with a favorable safety profile in patients with relapsed or refractory CD30-positive lymphomas...
  2. doi request reprint From drug discovery to biomarker-driven clinical trials in lymphoma
    Anas Younes
    Department of Lymphoma Myeloma, MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Nat Rev Clin Oncol 9:643-53. 2012
    ..We review the current status of biomarker development in lymphoma, and discuss novel biomarker-directed clinical trial designs for lymphoma...
  3. doi request reprint Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial
    Anas Younes
    Department of Lymphoma and Myeloma, The University of Texas, M D Anderson Cancer Center, Houston, TX 77030, USA
    Lancet Oncol 12:1222-8. 2011
    ..We tested the safety and efficacy of mocetinostat, an oral isotype-selective histone deacetylase inhibitor, in patients with relapsed classical Hodgkin's lymphoma...
  4. doi request reprint Phase I study of a novel oral Janus kinase 2 inhibitor, SB1518, in patients with relapsed lymphoma: evidence of clinical and biologic activity in multiple lymphoma subtypes
    Anas Younes
    Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 30:4161-7. 2012
    ..We conducted a phase I dose-finding and pharmacokinetic/pharmacodynamic study of SB1518, a potent JAK2 inhibitor, in patients with relapsed lymphoma...
  5. doi request reprint Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/refractory B-cell lymphoma
    Anas Younes
    Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 30:2776-82. 2012
    ..We determine the maximum-tolerated dose (MTD), pharmacokinetics, safety, and preliminary efficacy of SAR3419, an antibody-drug conjugate targeting CD19, in a first-in-man phase I clinical trial in patients with relapsed lymphoma...
  6. doi request reprint Panobinostat in patients with relapsed/refractory Hodgkin's lymphoma after autologous stem-cell transplantation: results of a phase II study
    Anas Younes
    MD Anderson Cancer Center, 1515 Holcombe Blvd, Unite 429, Houston, TX 77030, USA
    J Clin Oncol 30:2197-203. 2012
    ..Hodgkin's lymphoma (HL) has no standard of care for patients who are relapsed or refractory to autologous stem-cell transplantation (ASCT). This phase II study examined safety and activity of panobinostat in this population...
  7. pmc Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma
    Anas Younes
    Departments of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Blood 119:4123-8. 2012
    ..Our results demonstrate that the addition of rituximab to ABVD is safe and has a promising clinical activity in patients with advanced-stage cHL. These data are currently being confirmed in a multicenter randomized trial...
  8. pmc Histone deacetylase inhibitors in Hodgkin lymphoma
    Daniela Buglio
    Department of Lymphoma Myeloma, 1515 Holcombe Boulevard, Box 429, Houston, TX 77030, USA
    Invest New Drugs 28:S21-7. 2010
    ..This review will focus on the emerging role of histone deacetylase inhibitors in patients with relapsed HL...
  9. doi request reprint CD30-targeted antibody therapy
    Anas Younes
    Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Curr Opin Oncol 23:587-93. 2011
    ..This article reviews the current knowledge of therapeutic targeting of CD30+ cancers using naked and conjugated monoclonal antibodies...
  10. ncbi request reprint Initial trials of anti-CD80 monoclonal antibody (Galiximab) therapy for patients with relapsed or refractory follicular lymphoma
    Anas Younes
    M D Anderson Cancer Center, University of Texas, Houston, TX 77030 4009, USA
    Clin Lymphoma 3:257-9. 2003
  11. ncbi request reprint Clinicopathologic and molecular features of Hodgkin's lymphoma
    Anas Younes
    Department of Lymphoma Myeloma, MD Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Biol Ther 2:500-7. 2003
    ..Novel treatment strategies based on our understanding of Hodgkin's lymphoma biology are currently being explored to maintain the high cure rate without the added treatment related toxicity...
  12. pmc Beyond chemotherapy: new agents for targeted treatment of lymphoma
    Anas Younes
    Department of Lymphoma and Myeloma, Unit 429, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Nat Rev Clin Oncol 8:85-96. 2011
    ..This Review summarizes the current development status of novel agents for lymphoma and discusses strategies to move the field forward...
  13. ncbi request reprint Nuclear transcription factor-kappaB in Hodgkin's disease
    Anas Younes
    Department of Lymphoma Myeloma, The University of Texas, M D Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 429 Houston, TX 77030, USA
    Leuk Lymphoma 44:929-35. 2003
    ..Numerous studies have shown that Hodgkin's disease cells exhibit constitutive active NF-kappaB. The present review examines the mechanism how NF-kappaB is activated and its relevance to Hodgkin's disease...
  14. ncbi request reprint A pilot study of rituximab in patients with recurrent, classic Hodgkin disease
    Anas Younes
    Department of Lymphoma Myeloma, The University of Texas, M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 98:310-4. 2003
    ..Rituximab is used to primarily deplete normal B cells from HD lesions...
  15. ncbi request reprint Phase II clinical trial of interleukin-12 in patients with relapsed and refractory non-Hodgkin's lymphoma and Hodgkin's disease
    Anas Younes
    Department of Lymphoma and Myeloma, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 10:5432-8. 2004
    ..The purpose of this study was to evaluate the clinical activity and toxicity of recombinant human Interleukin (IL)-12 in patients with relapsed and refractory non-Hodgkin's lymphoma (NHL) or Hodgkin's disease (HD)...
  16. pmc Utility of mTOR inhibition in hematologic malignancies
    Anas Younes
    Department of Lymphoma Myeloma, M D Anderson Cancer Center, Houston, Texas 77030, USA
    Oncologist 16:730-41. 2011
    ..Thus far, promising results have been seen with the application of mTOR inhibitors as single agents in patients with relapsed or refractory leukemia, HL, NHL, MM, and WM...
  17. ncbi request reprint A phase II study of heat shock protein-peptide complex-96 vaccine therapy in patients with indolent non-Hodgkin's lymphoma
    Anas Younes
    Section of Lymphoma Myeloma, M D Anderson Cancer Center, Houston, TX, USA
    Clin Lymphoma 4:183-5. 2003
  18. pmc A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphoma
    A Younes
    MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030 4009, USA
    Br J Cancer 103:1783-7. 2010
    ....
  19. doi request reprint Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas
    Anas Younes
    Department of Lymphoma and Myeloma, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    N Engl J Med 363:1812-21. 2010
    ....
  20. pmc Predicting treatment outcome in classical Hodgkin lymphoma: genomic advances
    Enrico Derenzini
    Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, Texas, USA
    Genome Med 3:26. 2011
    ..In this review, we focus on the prognostic tools and biomarkers that are available for newly diagnosed HL, and we highlight recent advances in the genomic characterization of classical HL and potential targets for therapy...
  21. ncbi request reprint Therapeutic activity of mTOR inhibitors in mantle cell lymphoma: clues but no clear answers
    Anas Younes
    Department of Lymphoma Myeloma, M D Anderson Cancer Center, Houston, Texas 77030, USA
    Autophagy 4:707-9. 2008
    ..Here, we discuss the potential molecular mechanisms underlying this activity, and how to improve the therapeutic value of mTOR inhibitors by combining them with other agents that may target different molecular pathways...
  22. ncbi request reprint Angiogenesis in lymphoma: a short review
    Anas Younes
    Department of Lymphoma Myeloma, M D Anderson Cancer Center, Houston, TX 77030, USA
    Curr Mol Med 5:609-13. 2005
    ..This short review focuses on recent advances in angiogenesis-research in non-Hodgkin's lymphoma and Hodgkin's disease...
  23. ncbi request reprint Safety and efficacy of once-per-cycle pegfilgrastim in support of ABVD chemotherapy in patients with Hodgkin lymphoma
    Anas Younes
    Department of Lymphoma and Myeloma, The University of Texas, M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Eur J Cancer 42:2976-81. 2006
    ..Pegfilgrastim was found to be safe in support of ABVD chemotherapy that is administered every 14 d. Pegfilgrastim was also effective in maintaining ABVD dose intensity, and keeping planned dose of chemotherapy on schedule...
  24. ncbi request reprint Experience with 9-cis retinoic acid in patients with relapsed and refractory non-Hodgkin's lymphoma
    A Younes
    Department of Lymphoma and Myeloma, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Leuk Lymphoma 40:79-85. 2000
    ..We conclude that 9-cis RA has a modest activity in relapsed and refractory NHL. In this study, responses were observed in patients with B-cell lymphomas and those with T-cell lymphomas...
  25. ncbi request reprint A prospective randomized study to compare the molecular response rates between central lymphatic irradiation and intensive alternating triple chemotherapy in the treatment of stage I-III follicular lymphoma
    Chul S Ha
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 63:188-93. 2005
    ..MR was defined as disappearance of t(14;18) (q32;q21) amplified by polymerase chain reaction (PCR)...
  26. ncbi request reprint Radiotherapy alone for lymphocyte-predominant Hodgkin's disease
    Pamela J Schlembach
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston 77030 4009, USA
    Cancer J 8:377-83. 2002
    ..The purpose of the study was to analyze the results with radiotherapy alone in a select group of asymptomatic adults with nonbulky, early-stage lymphocyte-predominant Hodgkin's disease...
  27. doi request reprint Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma
    Jorge E Romaguera
    Department of Lymphoma Myeloma, University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Br J Haematol 150:200-8. 2010
    ..We conclude that intense chemoimmunotherapy without stem cell transplantation is effective for untreated aggressive MCL...
  28. ncbi request reprint High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine
    Jorge E Romaguera
    Department of Lymphoma, Unit 429, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 23:7013-23. 2005
    ..To determine the response, failure-free survival (FFS), and overall survival rates and toxicity of rituximab plus an intense chemotherapy regimen in patients with previously untreated aggressive mantle-cell lymphoma (MCL)...
  29. pmc The pan-deacetylase inhibitor panobinostat induces cell death and synergizes with everolimus in Hodgkin lymphoma cell lines
    Manuela Lemoine
    Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Blood 119:4017-25. 2012
    ....
  30. ncbi request reprint Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphoma
    Yasuhiro Oki
    Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 112:831-6. 2008
    ..The objective of this phase 2 trial was to investigate the activity of gemcitabine in combination with rituximab in patients with recurring or refractory HL...
  31. ncbi request reprint Pegfilgrastim administered in a single fixed dose is effective in inducing neutrophil count recovery after paclitaxel and topotecan chemotherapy in patients with relapsed aggressive non-Hodgkin's lymphoma
    Barbara Pro
    Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Leuk Lymphoma 47:481-5. 2006
    ..In these previously treated patients with NHL, a single dose of pegfilgrastim was effective in promoting neutrophil count recovery after paclitaxel and topotecan, and allowed patients to receive the next planned dose on time...
  32. ncbi request reprint Inhibition of heat shock protein 90 function by 17-allylamino-17-demethoxy-geldanamycin in Hodgkin's lymphoma cells down-regulates Akt kinase, dephosphorylates extracellular signal-regulated kinase, and induces cell cycle arrest and cell death
    Georgios V Georgakis
    Department of Lymphoma and Myeloma, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Clin Cancer Res 12:584-90. 2006
    ....
  33. ncbi request reprint The HSP90 inhibitor 17-AAG synergizes with doxorubicin and U0126 in anaplastic large cell lymphoma irrespective of ALK expression
    Georgios V Georgakis
    Departments of Lymphoma and Myeloma, The University of Texas, M D Anderson Cancer Center, Houston, TX 77030, USA
    Exp Hematol 34:1670-9. 2006
    ....
  34. doi request reprint Prospective phase II study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse large B-cell lymphoma
    Yasuhiro Oki
    Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Br J Haematol 163:611-20. 2013
    ..In conclusion, R-HCVAD/R-MA is associated with excellent outcome in patients ≤45 years old. However, in patients >45 years old, R-HCVAD/R-MA is associated with unacceptable mortality rates. ..
  35. ncbi request reprint Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL-R1 and TRAIL-R2 in primary and cultured lymphoma cells: induction of apoptosis and enhancement of doxorubicin- and bortezomib-induced cell death
    Georgios V Georgakis
    Department of Lymphoma Myeloma, M D Anderson Cancer Center MDACC, Houston, TX 77030, USA
    Br J Haematol 130:501-10. 2005
    ..Our data demonstrate that HGS-ETR1 and HGS-ETR2 monoclonal antibodies can induce cell death in a variety of cultured and primary lymphoma cells, and may have therapeutic value in lymphoma...
  36. ncbi request reprint Induction of cell cycle arrest and apoptosis by the proteasome inhibitor PS-341 in Hodgkin disease cell lines is independent of inhibitor of nuclear factor-kappaB mutations or activation of the CD30, CD40, and RANK receptors
    Bei Zheng
    Departments of Lymphoma Myeloma, Bioimmunotherapy, and Cancer Biology, M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 10:3207-15. 2004
    ..Cell cycle analysis was determined by flow cytometry. Intracellular protein levels were determined by Western blot...
  37. ncbi request reprint Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma
    Andre Goy
    Department of Lymphoma and Myeloma, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Box 459, Houston, TX 77030, USA
    J Clin Oncol 23:667-75. 2005
    ..Evaluate efficacy and toxicity of bortezomib in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma...
  38. pmc The histone deacetylase inhibitor entinostat (SNDX-275) induces apoptosis in Hodgkin lymphoma cells and synergizes with Bcl-2 family inhibitors
    Adam Jona
    Department of Lymphoma and Myeloma, The University of Texas M D Anderson Cancer Center, Houston, USA
    Exp Hematol 39:1007-1017.e1. 2011
    ..Based on promising in vitro and in vivo activity of several histone deacetylase inhibitors in Hodgkin lymphoma (HL), we investigated SNDX-275, an oral class 1 isoform-selective histone deacetylase inhibitors in HL-derived cell lines...
  39. doi request reprint Long term results of a phase 2 study of vincristine sulfate liposome injection (Marqibo(®) ) substituted for non-liposomal vincristine in cyclophosphamide, doxorubicin, vincristine, prednisone with or without rituximab for patients with untreated aggressi
    Fredrick Hagemeister
    University of Texas M D Anderson Cancer Center UTMDACC, Houston, TX 77030, USA
    Br J Haematol 162:631-8. 2013
    ..This enhanced activity probably reflects VCR dose intensification, pharmacokinetic optimization, and enhanced delivery afforded by VSLI. A Phase 3 trial of R-CHMP versus R-CHOP in elderly patients with untreated DLBCL is ongoing...
  40. ncbi request reprint Immunosuppression and infectious complications in patients with stage IV indolent lymphoma treated with a fludarabine, mitoxantrone, and dexamethasone regimen
    Apostolia Maria Tsimberidou
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 104:345-53. 2005
    ....
  41. ncbi request reprint Fludarabine, mitoxantrone, dexamethasone (FND) compared with an alternating triple therapy (ATT) regimen in patients with stage IV indolent lymphoma
    Apostolia M Tsimberidou
    Department of Lymphoma and Myeloma, University of Texas, M D Anderson Cancer Center, Houston 77030, USA
    Blood 100:4351-7. 2002
    ..In conclusion, both regimens were associated with high rates of response and survival. ATT was associated with substantially longer FFS, but it was more toxic than FND...
  42. ncbi request reprint Analysis of in-field control and late toxicity for adults with early-stage Hodgkin's disease treated with chemotherapy followed by radiotherapy
    Gregory M Chronowski
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Int J Radiat Oncol Biol Phys 55:36-43. 2003
    ..Cardiac toxicity and second malignancies, particularly the incidence of solid tumors in terms of the RT field size treated, were also examined...
  43. ncbi request reprint Cytomegalovirus infection in patients with lymphoma: an important cause of morbidity and mortality
    Harrys A Torres
    Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    Clin Lymphoma Myeloma 6:393-8. 2006
    ..We sought to determine the risk factors and outcome of CMV-A and CMV-D among patients with lymphoma...
  44. pmc The class-I HDAC inhibitor MGCD0103 induces apoptosis in Hodgkin lymphoma cell lines and synergizes with proteasome inhibitors by an HDAC6-independent mechanism
    Daniela Buglio
    M D Anderson Cancer Center, Department of Lymphoma Myeloma, Houston, University of Texas, TX, USA
    Br J Haematol 151:387-96. 2010
    ..Thus, our results demonstrate that MGCD0103 may synergize with proteasome inhibitors by HDAC6-independent mechanisms, providing mechanistic rationale for exploring this potentially less toxic combination for the treatment of lymphoma...
  45. ncbi request reprint Phase II study of denileukin diftitox for relapsed/refractory B-Cell non-Hodgkin's lymphoma
    Nam H Dang
    The University of Texas M D Anderson Cancer Center, Department of Lymphoma Myeloma, 1515 Holcombe Blvd, Box 429, Houston, TX 77030, USA
    J Clin Oncol 22:4095-102. 2004
    ..A phase II study was performed to evaluate the efficacy and tolerability of denileukin diftitox for relapsed or refractory B-cell NHL...
  46. doi request reprint Temsirolimus downregulates p21 without altering cyclin D1 expression and induces autophagy and synergizes with vorinostat in mantle cell lymphoma
    Victor Y Yazbeck
    Department of Lymphoma Myeloma, The University of Texas M D Anderson Cancer Center, Houston, Tex 77030, USA
    Exp Hematol 36:443-50. 2008
    ..To investigate the mechanisms of antiproliferative effect induced by the mammalian target of rapamycin (mTOR) inhibitor temsirolimus in mantle cell lymphoma (MCL)...
  47. doi request reprint Phase II study of yttrium-90-ibritumomab tiuxetan in patients with relapsed or refractory mantle cell lymphoma
    Michael Wang
    Department of Lymphoma and Myeloma, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 27:5213-8. 2009
    ..This phase II trial evaluated the safety and efficacy of yttrium-90 ((90)Y)-ibritumomab tiuxetan in patients with relapsed or refractory mantle cell lymphoma (MCL)...
  48. ncbi request reprint Phase 2 study of fludarabine and paclitaxel in patients with recurrent low-grade non-Hodgkin's lymphoma
    Barbara Pro
    Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Leuk Lymphoma 47:1818-21. 2006
    ..The combination of fludarabine and paclitaxel has clinical activity in patients with recurrent low-grade NHL...
  49. ncbi request reprint Prophylactic use of filgrastim with ABVD and BEACOPP chemotherapy regimens for Hodgkin lymphoma
    Amanda Wedgwood
    Department of Lymphoma Myeloma, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Clin Lymphoma Myeloma 8:S63-6. 2007
    ..However, randomized studies are needed to clarify the role of primary prophylaxis with ABVD and BEACOPP-baseline regimens. Secondary prophylaxis should be considered in all patients, especially those who develop neutropenic fever...
  50. ncbi request reprint Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphomas
    Issa F Khouri
    Department of Blood and Marrow Transplantation, Unit 423, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Clin Oncol 23:2240-7. 2005
    ....
  51. ncbi request reprint Pretransplant positive positron emission tomography/gallium scans predict poor outcome in patients with recurrent/refractory Hodgkin lymphoma
    Elias Jabbour
    Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 109:2481-9. 2007
    ....
  52. ncbi request reprint Inhibition of the phosphatidylinositol-3 kinase/Akt promotes G1 cell cycle arrest and apoptosis in Hodgkin lymphoma
    Georgios V Georgakis
    Department of Lymphoma and Myeloma, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Br J Haematol 132:503-11. 2006
    ..Our data suggest that PTEN phosphorylation and activation of CD30, CD40 and RANK may play a role in activating Akt in HRS cells...
  53. ncbi request reprint The heat shock protein 90 inhibitor 17-AAG induces cell cycle arrest and apoptosis in mantle cell lymphoma cell lines by depleting cyclin D1, Akt, Bid and activating caspase 9
    Georgios V Georgakis
    Department of Lymphoma and Myeloma, The University of Texas, MD Anderson Cancer Center MDACC, Houston, TX, USA
    Br J Haematol 135:68-71. 2006
    ..These data suggest that 17-AAG may have a potential therapeutic value in patients with MCL...
  54. doi request reprint Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study
    Anas Younes
    University of Texas MD Anderson Cancer Center, Houston, TX, USA Electronic address
    Lancet Oncol 14:1348-56. 2013
    ..We aimed to assess the safety and early clinical efficacy of this drug as first-line treatment in combination with standard or modified-standard treatment in patients with previously untreated Hodgkin's lymphoma...
  55. doi request reprint Phase II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in combination with rituximab in patients with recurrent B-cell non-Hodgkin lymphoma
    Barbara Pro
    Department of Lymphoma Myeloma, MD Anderson Cancer Center, Houston, TX, USA
    Br J Haematol 143:355-60. 2008
    ..In conclusion, oblimersen sodium can be safely combined with rituximab. The combination appears to be most beneficial in patients with indolent NHL and warrants further investigation in a large randomized trial...
  56. doi request reprint High-dose chemotherapy and autologous stem cell transplantation for nodular lymphocyte-predominant Hodgkin lymphoma
    Meghan Karuturi
    Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Biol Blood Marrow Transplant 19:991-4. 2013
    ..Our data suggest that high-dose chemotherapy and autologous transplantation should be considered as an option for patients with relapsed NLPHL...
  57. ncbi request reprint Thalidomide for patients with recurrent lymphoma
    Barbara Pro
    Department of Lymphoma Myeloma, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 100:1186-9. 2004
    ..However, its activity against other lymphoid tumors is unknown. The authors reported their experience with thalidomide in patients with recurrent/refractory non-Hodgkin lymphoma and in patients with Hodgkin disease...
  58. pmc Detection of ABCC1 expression in classical Hodgkin lymphoma is associated with increased risk of treatment failure using standard chemotherapy protocols
    Wesley Greaves
    Department of Hematopathology, Unit 72, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA
    J Hematol Oncol 5:47. 2012
    ..ATP-binding cassette (ABC) transporters confer multidrug resistance in various cancers and ABCC1 overexpression has been shown to contribute to drug resistance in the CHL cell line, KMH2...
  59. doi request reprint Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial
    Michael Wang
    Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Lancet Oncol 13:716-23. 2012
    ....
  60. ncbi request reprint Nonablative allogeneic stem-cell transplantation for advanced/recurrent mantle-cell lymphoma
    Issa F Khouri
    Department of Blood and Marrow Transplantation, Unit 423, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Clin Oncol 21:4407-12. 2003
    ..Patients with relapsed mantle-cell lymphoma have poor prognosis and short survival. Our aim was to determine the efficacy of nonablative allogeneic stem-cell transplantation in patients with relapsed mantle-cell lymphoma...
  61. ncbi request reprint Experience with heat shock protein-peptide complex 96 vaccine therapy in patients with indolent non-Hodgkin lymphoma
    Yasuhiro Oki
    Department of Lymphoma and Myeloma, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 109:77-83. 2007
    ....
  62. doi request reprint Does rituximab have a place in treating classic hodgkin lymphoma?
    Yasuhiro Oki
    Department of Lymphoma and Myeloma, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 429, Houston, TX 77030, USA
    Curr Hematol Malig Rep 5:135-9. 2010
    ..These trials further clarify the role of rituximab in cHL. Enrollment of patients with this "classic" disease in clinical trials is encouraged...
  63. ncbi request reprint New molecular targets for treatment of lymphoma
    Barbara Pro
    Department of Lymphoma Myeloma, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 429, Houston, TX 77030, USA
    Curr Oncol Rep 6:360-8. 2004
    ..In this review, we focus on new molecular targets that are being explored for the treatment of non-Hodgkin's lymphoma and Hodgkin's disease...
  64. pmc HDAC11 plays an essential role in regulating OX40 ligand expression in Hodgkin lymphoma
    Daniela Buglio
    Departments of Lymphoma and Myeloma, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Blood 117:2910-7. 2011
    ..These results demonstrate for the first time that HDAC11 plays an essential role in regulating OX40L expression. Pharmacologic inhibition of HDAC11 may produce a favorable antitumor immune response in patients with HL...
  65. doi request reprint Phase I Study of Panobinostat plus Everolimus in Patients with Relapsed or Refractory Lymphoma
    Yasuhiro Oki
    Authors Affiliations Departments of Lymphoma Myeloma, Diagnostic Imaging, and Biostatistics, The University of Texas, M D Anderson Cancer Center, Houston, Texas
    Clin Cancer Res 19:6882-90. 2013
    ..The concept was supported by the single-agent clinical activity of histone deacetylase inhibitors and mTOR inhibitors, and on the in vitro mechanism-based synergistic antiproliferative activity...
  66. pmc Salinosporamide A (NPI-0052) potentiates apoptosis, suppresses osteoclastogenesis, and inhibits invasion through down-modulation of NF-kappaB regulated gene products
    Kwang Seok Ahn
    Cytokine Research Laboratory, Department of Experimental Therapeutics, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 110:2286-95. 2007
    ..Thus, overall, our results indicate that salinosporamide A enhances apoptosis, suppresses osteoclastogenesis, and inhibits invasion through suppression of the NF-kappaB pathway...
  67. pmc Vorinostat inhibits STAT6-mediated TH2 cytokine and TARC production and induces cell death in Hodgkin lymphoma cell lines
    Daniela Buglio
    Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Blood 112:1424-33. 2008
    ....
  68. ncbi request reprint Clinical implications of the tumor necrosis factor family in benign and malignant hematologic disorders
    Anas Younes
    Department of Lymphoma and Myeloma, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 98:458-67. 2003
    ..The potential therapeutic use of these members also is discussed...
  69. ncbi request reprint Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center
    Qi Liu
    Department of Lymphoma Myeloma, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 24:1582-9. 2006
    ..Advanced-stage follicular lymphoma is considered incurable. The pace of improvements in treatment has been slow. This article analyzes five sequential cohorts of patients with stage IV follicular lymphoma treated between 1972 and 2002...
  70. ncbi request reprint Expression of heat-shock protein-90 in non-Hodgkin's lymphomas
    Jose R Valbuena
    Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Mod Pathol 18:1343-9. 2005
    ..These data suggest that many lymphoma types are suitable targets for modulation of HSP90 activity, and that HSP90 inhibitors are a potential investigational therapy for lymphoma patients...
  71. ncbi request reprint MEK/ERK pathway is aberrantly active in Hodgkin disease: a signaling pathway shared by CD30, CD40, and RANK that regulates cell proliferation and survival
    Bei Zheng
    Department of Lymphoma Myeloma, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 429, Houston, TX 77030, USA
    Blood 102:1019-27. 2003
    ..These findings provide a proof-of-principle that inhibition of the MEK/ERK pathway may have therapeutic value in HD...
  72. doi request reprint Prognostic value of serum CD44, intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 levels in patients with indolent non-Hodgkin lymphomas
    Nina Shah
    University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Leuk Lymphoma 53:50-6. 2012
    ..Though the FLIPI model remains the gold standard for prognosis, these quantitative serologic markers may be useful as adjunct tools in assessing disease risk...
  73. pmc Hodgkin lymphoma risk: role of genetic polymorphisms and gene-gene interactions in DNA repair pathways
    Claudia M Monroy
    Department of Epidemiology, M D Anderson Cancer Center, The University of Texas, Houston, Texas 77030, USA
    Mol Carcinog 50:825-34. 2011
    ..These findings suggest that DNA repair variants in BER and DSB pathways may play an important role in the development of HL...
  74. ncbi request reprint Heat-shock protein 90 inhibitors in cancer therapy: 17AAG and beyond
    Georgios V Georgakis
    The University of Texas, Department of Lymphoma and Myeloma, MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Future Oncol 1:273-81. 2005
    ..This paper will review the recent advances in HSP90-biology and will discuss the emerging role of the HSP90 inhibitors such as 17-allylamino-17 demethoxy-geldanamycin and other HSP-90-directed small molecules in cancer therapy...
  75. ncbi request reprint Pentostatin in T-non-Hodgkin's lymphomas: efficacy and effect on CD26+ T lymphocytes
    Nam H Dang
    MD Anderson Cancer Center, Houston, TX 77030, USA
    Oncol Rep 10:1513-8. 2003
    ..We therefore conclude that while pentostatin is a safe and active agent for T-NHL regardless of CD26 expression, it may selectively deplete CD26+ T lymphocytes, with potentially significant clinical implications...
  76. pmc K1 protein of human herpesvirus 8 suppresses lymphoma cell Fas-mediated apoptosis
    Suizhao Wang
    Department of Lymphoma and Myeloma, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 109:2174-82. 2007
    ..K1 may contribute to lymphoma development by stimulating cell survival by selectively blocking Fas-mediated apoptosis...
  77. pmc Decreased sensitivity of 17p-deleted chronic lymphocytic leukemia cells to a small molecule BCL-2 antagonist ABT-737
    Kensuke Kojima
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 118:1023-31. 2012
    ..The role of p53 in sensitivity of CLL cells to BCL-2 inhibition has not been extensively investigated...
  78. ncbi request reprint Novel small-molecule therapy of Hodgkin lymphoma
    Daniela Buglio
    Department of Lymphoma Myeloma, MD Anderson Cancer Center, Houston, TX 77030, USA
    Expert Rev Anticancer Ther 7:735-40. 2007
    ..In this review we focus on emerging novel therapies using small molecules that target specific survival pathways in the cancer cells. This approach is aimed at improving the cure rate while reducing treatment-related toxicity...
  79. ncbi request reprint Emerging applications of the tumor necrosis factor family of ligands and receptors in cancer therapy
    Anas Younes
    Department of Lymphoma and Myeloma, Unit 429, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Clin Oncol 21:3526-34. 2003
    ....
  80. ncbi request reprint Phase II study of oxaliplatin in patients with recurrent or refractory non-Hodgkin lymphoma
    Yasuhiro Oki
    Department of Lymphoma Myeloma, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Cancer 104:781-7. 2005
    ..Oxaliplatin is a platinum derivative with a broad range of anticancer activity. The objective of the current Phase II trial was to investigate the activity of oxaliplatin in patients with recurrent or refractory non-Hodgkin lymphoma (NHL)...
  81. ncbi request reprint Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphoma
    Jorge E Romaguera
    Department of Lymphoma Myeloma, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Cancer 97:586-91. 2003
    ..The impact of endoscopic assessment on the management of MCL patients is unknown...
  82. ncbi request reprint Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality
    I F Khouri
    Department of Blood and Marrow Transplantation, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Blood 98:3595-9. 2001
    ..Further studies are warranted to compare nonablative allogeneic hematopoietic transplantation with alternative treatment strategies...
  83. ncbi request reprint New treatment strategies for aggressive lymphoma
    Anas Younes
    Department of Lymphoma Myeloma, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Semin Oncol 31:10-3. 2004
    ..Consequently, the CHOP-14 regimen (in which the dose intensity is 50% greater than that of the standard regimen) has been adopted by many oncologists for the treatment of aggressive NHL...
  84. ncbi request reprint Peroxisome proliferator-activated receptor gamma and retinoid X receptor ligands are potent inducers of differentiation and apoptosis in leukemias
    Marina Konopleva
    Section of Molecular Hematology and Therapy and Department of Blood and Marrow Transplantation, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Mol Cancer Ther 3:1249-62. 2004
    ....
  85. ncbi request reprint Lack of c-kit (CD117) expression in CD30+ lymphomas and lymphomatoid papulosis
    George Z Rassidakis
    Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Mod Pathol 17:946-53. 2004
    ....
  86. ncbi request reprint Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma
    Michelle A Fanale
    Department of Lymphoma Myeloma, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Drugs 67:333-50. 2007
    ....
  87. ncbi request reprint Histone deacetylase inhibitors in the treatment of lymphoma
    Manuela Lemoine
    Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, 77030, USA
    Discov Med 10:462-70. 2010
    ..This review focuses on the use of HDAC inhibitors in the treatment of relapsed lymphoma...
  88. ncbi request reprint Impact of high-dose chemotherapy on peripheral T-cell lymphomas
    J Rodriguez
    Department of Blood and Marrow Transplantation, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 19:3766-70. 2001
    ..Considering the dismal outcome of conventional chemotherapy in PTCL patients, these data suggest the hypothesis that the poor prognostic implication of T-cell phenotyping in NHL might be overcome by frontline HDCT and transplantation...
  89. ncbi request reprint European Organization for Research and Treatment of Cancer and Groupe d'Etude des Lymphomes de l'Adulte very favorable and favorable, lymphocyte-predominant Hodgkin disease
    Richard B Wilder
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Cancer 94:1731-8. 2002
    ....
  90. ncbi request reprint Cytomegalovirus pneumonia in patients with lymphoma
    Roy F Chemaly
    Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, 77230, USA
    Cancer 104:1213-20. 2005
    ..Even when treated with antiviral therapy, cytomegalovirus pneumonia (CMVp) is associated with high morbidity and mortality in immunocompromised patients. CMVp has been rarely reported in patients with lymphoma...
  91. ncbi request reprint From Rapa Nui to rapamycin: targeting PI3K/Akt/mTOR for cancer therapy
    Georgios V Georgakis
    Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Expert Rev Anticancer Ther 6:131-40. 2006
    ..This article provides a brief analysis of the PI3K/Akt/mTOR pathway, its importance in tumor pathogenesis and the current status of preclinical and clinical studies targeting signaling components of this pathway...
  92. doi request reprint Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience
    Paolo Anderlini
    The U T M D Anderson Cancer Center, Department of Stem Cell Transplantation and Cellular Therapy 1515 Holcombe Boulevard, Unit 423, Houston, TX 77030 USA
    Haematologica 93:257-64. 2008
    ..We here present an update of our single-center experience with fludarabine-melphalan as a preparative regimen...
  93. ncbi request reprint Hodgkin's lymphoma: molecular targets and novel treatment strategies
    Victor Yazbeck
    MD Anderson Cancer Center, Department of Lymphoma Myeloma, Houston, Texas, USA
    Future Oncol 2:533-51. 2006
    ..Future treatment strategies will also be discussed based on our understanding of HL biology...
  94. ncbi request reprint Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin's disease: low transplant-related mortality and impact of intensity of conditioning regimen
    P Anderlini
    Department of Blood and Marrow Transplantation, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Bone Marrow Transplant 35:943-51. 2005
    ..03), and a trend towards better progression-free survival (37 vs 21% at 18 months; P=0.2). RIC allo-SCT is feasible in relapsed/refractory HD patients with a low TRM. The intensity of the preparative regimen affects survival...
  95. ncbi request reprint Paclitaxel plus topotecan treatment for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma
    A Younes
    Department of Lymphoma and Myeloma, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Ann Oncol 12:923-7. 2001
    ..We conducted a phase II clinical trial to investigate the activity and tolerability of the combination of both drugs...
  96. ncbi request reprint Infusional vinorelbine in relapsed or refractory lymphomas
    A H Sarris
    Department of Lymphoma and Myeloma, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Leuk Lymphoma 39:291-9. 2000
    ..The role of vinorelbine in combination regimens for patients with relapsed lymphomas, particularly those of indolent histology, should be further investigated...
  97. ncbi request reprint Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma
    I F Khouri
    Department of Hematology, The University of Texas, M D Anderson Cancer Center, Houston 77030, USA
    J Clin Oncol 16:3803-9. 1998
    ..After four courses, patients were consolidated with high-dose CY, total-body irradiation, and autologous or allogeneic blood or marrow stem-cell transplantation...
  98. ncbi request reprint The addition of rituximab to CHOP chemotherapy improves overall and failure-free survival for follicular grade 3 lymphoma
    M J Overman
    Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Ann Oncol 19:553-9. 2008
    ..The benefit of adding rituximab to anthracycline-based therapy for follicular lymphoma grade 3 has not been studied...
  99. ncbi request reprint Irinotecan in relapsed or refractory non-Hodgkin's lymphoma
    A H Sarris
    Department of Lymphoma and Myeloma, The University of Texas, M D Anderson Cancer Center, Houston 77030, USA
    Oncology (Williston Park) 15:53-6. 2001
    ..Accrual to this study is continuing for better determination of the response rate in all histologic subtypes of non-Hodgkin's lymphoma...
  100. ncbi request reprint Targeting lymphoma cells and their microenvironment with novel antibodies
    Amanda Wedgwood
    Department of Lymphoma Myeloma, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Clin Lymphoma Myeloma 7:S33-40. 2006
    ..Continued investigation is encouraged to combine monoclonal antibodies with other targeted therapies and incorporate their use into standards of care in the treatment of lymphoma...
  101. ncbi request reprint Rituximab: review and clinical applications focusing on non-Hodgkin's lymphoma
    K M King
    Division of Pharmacy, University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Expert Rev Anticancer Ther 1:177-86. 2001
    ..Furthermore, it is currently being evaluated in several nonmalignant diseases, such as autoimmune disorders. This review will focus on the role of rituximab in patients with non-Hodgkin's lymphoma...

Research Grants3

  1. Clinical Activity of 17-AAG in Lymphoma
    Anas Younes; Fiscal Year: 2007
    ..In Aim 3 we will correlate the biologic effects of 17-AAG and clinical response in patients with relapsed MCL, ALCL, and HL. ..